SPIRO(CYCLOHEXANE-1,3'(1'H)-FURO(3,4-C)PYRIDINE)-4-CARBOXAMIDE, N-(1-(2-FLUOROPHENYL)-1H-PYRAZOL-3-YL)-1'-OXO-, TRANS-
Schizophrenia
Merck Sharp & Dohme LLCSmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 65/ 100
Competitive context
145 Active assets in the Schizophrenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lurasidone Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 4 | BBB |
Asenapine Noven Pharmaceuticals, Inc. | Phase 4 | BBB |
Xanomeline European Group for Research In Schizophrenia | Phase 4 | BBB |
TROSPIUM European Group for Research In Schizophrenia | Phase 4 | BBB |
Opc-34712 Humanis Saglık Anonim Sirketi | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
SPIRO(CYCLOHEXANE-1,3'(1'H)-FURO(3,4-C)PYRIDINE)-4-CARBOXAMIDE, N-(1-(2-FLUOROPHENYL)-1H-PYRAZOL-3-YL)-1'-OXO-, TRANS- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →